Eminent specialist surgical oncologist Associate Professor David Gyorki, together with Associate Professor Anne Hamilton, and colleagues from Royal Prince Alfred Hospital led by Associate Professor Peter Grimison, Princess Alexandra Hospital led by Professor Andrew Barbour collaborating with the national scientific body for sarcoma, ANZSA, have received a sizeable grant from the Medical Research Future Fund (MRFF) under the Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) scheme.
The grant is to run the international trial in Australia – “A randomised phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)”.
“Eligible Australian patients with retroperitoneal sarcoma at high risk of recurrence will be able to participate in this randomised controlled trial designed to answer the question of whether preoperative chemotherapy improves outcome for patients. The current standard of care for these patients is surgery alone. However, the risk of recurrence for many of them is 50% or higher.
The purpose of the STRASS 2 trial is to determine whether the administration of chemotherapy before surgery represents a better treatment compared to surgery alone and if the administration of chemotherapy before surgery is safe. It is also to assess whether specific chemotherapy can be used to reduce recurrence risk in a patient with either high-grade leiomyosarcoma or high-grade dedifferentiated liposarcoma.
It is the first time a trial has studied the role of preoperative chemotherapy specifically in patients with retroperitoneal sarcoma, an anatomical location with unique challenges and disease patterns.” (ANZSA, July 2021)
The trial, led by the European Organisation for Research and Treatment of Cancer (EORTC) has participation from Europe, Canada, USA and now Australia.
“With aims to recruit 40 Australian patients, the STRASS 2 trial will open at Peter MacCallum Cancer Centre (VIC) as the lead site, with A/Prof Hamilton as the lead oncologist on the trial. The trial will also open at Royal Prince Alfred/Chris O’Brien Lifehouse (NSW) and at the Princess Alexandra Hospital (QLD).
About clinical trial
Please speak to your treating team about this clinical trial to see if you are eligible for it.
Remember that participation in a clinical trial is voluntary and that you should never feel forced to participate in it.
Before you agree to participate in a clinical trial, it is important to be as informed as possible. It can be helpful to write down questions you have before seeing your doctor.” (ANZSA, July 2021)
Please refer to the ANZSA website for further information by pressing the link below